ACADIA PHARMACEUTICALS INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ACADIA PHARMACEUTICALS INC. (ACAD) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 14.93 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 14.93M shares, a 23.81% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 11.65M shares, a 35.38% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 15.86M shares, a 21.57% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 19.59M shares, a 6.44% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 17.30M shares, a 5.12% decline from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 18.23M shares, a 14.25% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 21.26M shares, a 0.37% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 21.18M shares, a 20.82% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 14.93M shares 10-Q · filed 2026-08-05 | 13.97M shares 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | 11.65M shares 10-Q · filed 2026-05-07 | |||||||
| 2025-12-31 | 17.30M shares 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | 15.86M shares 10-Q · filed 2025-11-06 | 17.99M shares 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | 19.59M shares 10-Q · filed 2026-08-05 | 18.71M shares 10-Q · filed 2026-08-05 | 18.71K shares 10-Q · filed 2025-08-07 | |||||
| 2025-03-31 | 18.03M shares 10-Q · filed 2026-05-07 | |||||||
| 2024-12-31 | 18.23M shares 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | 20.22M shares 10-Q · filed 2025-11-06 | 18.44M shares 10-Q · filed 2025-11-06 | ||||||
| 2024-06-30 | 20.94M shares 10-Q · filed 2025-08-07 | 17.53K shares 10-Q · filed 2025-08-07 | 17.53M shares 10-Q · filed 2024-08-07 | |||||
| 2024-03-31 | 15.08M shares 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | 21.26M shares 10-K · filed 2026-02-26 | |||||||
| 2023-09-30 | 22.11M shares 10-Q · filed 2024-11-07 | 22.11M shares 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 16.38M shares 10-Q · filed 2024-08-07 | 23.17M shares 10-Q · filed 2024-08-07 | ||||||
| 2023-03-31 | 20.76M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | 21.18M shares 10-K · filed 2025-02-27 | |||||||
| 2022-09-30 | 21.65M shares 10-Q · filed 2023-11-03 | |||||||
| 2022-06-30 | 21.64M shares 10-Q · filed 2023-08-03 | 21.64M shares 10-Q · filed 2023-08-03 | 21.65M shares 10-Q · filed 2022-08-09 | |||||
| 2022-03-31 | 17.54M shares 10-Q · filed 2023-05-08 | |||||||
| 2021-12-31 | 17.54M shares 10-K · filed 2024-02-28 | |||||||
| 2021-09-30 | 18.57M shares 10-Q · filed 2022-11-03 | |||||||
| 2021-06-30 | 19.49M shares 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | 20.30M shares 10-Q · filed 2022-05-05 | |||||||
| 2020-12-31 | 19.33M shares 10-K · filed 2023-02-28 | |||||||
| 2020-09-30 | 19.70M shares 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | 19.93M shares 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | 21.06M shares 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | 19.52M shares 10-K · filed 2022-03-01 | |||||||
| 2019-09-30 | 20.91M shares 10-Q · filed 2020-11-04 | |||||||
| 2019-06-30 | 23.39M shares 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 20.62M shares 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | 20.82M shares 10-K · filed 2021-02-25 | |||||||
| 2018-09-30 | 19.77M shares 10-Q · filed 2019-10-31 | |||||||
| 2018-06-30 | 19.83M shares 10-Q · filed 2019-08-01 | |||||||
| 2018-03-31 | 18.08M shares 10-Q · filed 2019-05-02 | 18.08M shares 10-Q · filed 2018-05-04 | ||||||
| 2017-12-31 | 18.53M shares 10-K · filed 2020-02-27 | |||||||
| 2017-09-30 | 20.15M shares 10-Q · filed 2018-11-06 | |||||||
| 2017-06-30 | 16.56M shares 10-Q · filed 2018-08-08 | |||||||
| 2017-03-31 | 16.83M shares 10-Q · filed 2018-05-04 | |||||||
| 2016-12-31 | 14.74M shares 10-K · filed 2019-02-27 | |||||||
| 2016-09-30 | 14.46M shares 10-Q · filed 2017-11-07 | |||||||
| 2016-06-30 | 14.40M shares 10-Q · filed 2017-08-08 | |||||||
| 2016-03-31 | 14.51M shares 10-Q · filed 2017-05-09 | |||||||
| 2015-12-31 | 11.53M shares 10-K · filed 2018-02-27 | 11.53B shares 10-K · filed 2016-02-29 | ||||||
| 2015-09-30 | 12.35M shares 10-Q · filed 2015-11-05 | 12.31M shares 10-Q · filed 2016-11-07 | 11.60M shares 10-Q · filed 2015-11-05 | |||||
| 2015-06-30 | 11.99M shares 10-Q · filed 2015-08-06 | 12.20M shares 10-Q · filed 2016-08-04 | 11.29M shares 10-Q · filed 2015-08-06 | |||||
| 2015-03-31 | 11.81M shares 10-Q · filed 2016-05-05 | 10.86M shares 10-Q · filed 2015-05-07 | ||||||
| 2014-12-31 | 9.90M shares 10-K · filed 2017-02-28 | 9.74M shares 10-K · filed 2015-02-26 | ||||||
| 2014-09-30 | 9.75M shares 10-Q · filed 2015-11-05 | 9.70M shares 10-Q · filed 2015-11-05 | ||||||
| 2014-06-30 | 9.74M shares 10-Q · filed 2015-08-06 | 9.60M shares 10-Q · filed 2015-08-06 | ||||||
| 2014-03-31 | 9.64M shares 10-Q · filed 2015-05-07 | |||||||
| 2013-12-31 | 9.31B shares 10-K · filed 2016-02-29 | 10.36M shares 10-K · filed 2014-02-27 | ||||||
| 2013-09-30 | 10.52M shares 10-Q · filed 2014-11-10 | 10.72M shares 10-Q · filed 2014-11-10 | ||||||
| 2013-06-30 | 10.94M shares 10-Q · filed 2014-08-05 | 10.85M shares 10-Q · filed 2014-08-05 | ||||||
| 2013-03-31 | 10.72M shares 10-Q · filed 2014-05-06 | |||||||
| 2012-12-31 | 11.26M shares 10-K · filed 2015-02-26 | |||||||
| 2012-09-30 | 11.92M shares 10-Q · filed 2013-11-06 | 11.50M shares 10-Q · filed 2013-11-06 | ||||||
| 2012-06-30 | 11.83M shares 10-Q · filed 2013-08-06 | 11.39M shares 10-Q · filed 2013-08-06 | ||||||
| 2012-03-31 | 11.09M shares 10-Q · filed 2013-05-07 | |||||||
| 2011-12-31 | 9.97M shares 10-K · filed 2014-02-27 | |||||||
| 2011-09-30 | 10.41M shares 10-Q · filed 2012-11-05 | 9.83M shares 10-Q · filed 2012-11-05 | ||||||
| 2011-06-30 | 10.29M shares 10-Q · filed 2012-08-08 | 9.60M shares 10-Q · filed 2012-08-08 | ||||||
| 2010-12-31 | 4.91M shares 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |